semaglutide is fda approved New Weight Loss Medication Wegovy™ by the Semaglutide Safety Alerts, Recalls &

[13] [14] Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not receive GLP-1 medications due to the theoretical risk of thyroid C-cell tumors

84 GPs should screen for extraintestinal manifestations and also consider nonpharmacological management options that can provide symptom relief, such as physical exercise and physiotherapy for arthropathies

The oral semaglutide offered through MadeMed is a compounded sublingual formulation - it is not the same product, does not use the same proprietary absorption technology, and has not been independently evaluated by the FDA for bioavailability, dosing equivalence, or absorption characteristics relative to the FDA-approved version

Realistic Weight Loss Expectations Understanding what to actually expect helps prevent both disappointment and unrealistic optimism